Penicillin and Streptomycin are two prominent drugs used in the treatment of diseases caused due to bacteria. Penicillin refers to a group of antibiotics such as Pencilillium V, Penicillium G. Penicillin was first derived from Penicillium. Streptomycin is a bactericidal which is widely used in the treatment of Tuberculosis, along with other drugs. Streptomycin is also used to control fire blight in fruit trees. The market for Penicillin is segmented on the basis of the product type, end user, route of administration and geography.Among the product segments, formulations hold a larger market share than the bulk (Active Pharmaceutical Ingredient) manufacturing. The market for Penicillin and Streptomycin is estimated to be $XX million in 2015. It is estimated to grow at a CAGR of XX% during 2016-2021. The driving force behind the growth is rising number of infectious diseases, growing investments in research and development, innovations and government regulations. Increasing demand for generics and high incidences of anti-microbial resistance are the major factors which will drive the growth and development of new products in this market. However, stringent government regulations creating entry barriers and expiry of patents are the major challenges faced by Penicillin and Streptomycin market.
Geographically, North America holds the highest market share for Penicillin and Streptomycin market followed by Europe. The highest growth is going to be witnessed in Asia Pacific region, in countries such as India, China and Australia. The reason behind the growth is large population base improving healthcare infrastructure, rising health awareness and high disposable income.
Major players in this market are:
Pfizer (U.S),
Novartis (Switzerland),
Johnson & Johnson (U.S),
AstraZeneca (U.K),
GlaxoSmithKline (U.K),
Eli Lily (U.S),
Sanofi-Aventis (France)
Bristol-Myers Squibb (U.S).
“1. Global Penicillin and Streptomycin – Market Overview
2. Executive Summary
3. Global Penicillin and Streptomycin – Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End user profiling
3.2.3. Patent Analysis
3.2.4. Top 5 Financials Analysis
4. Global Penicillin and Streptomycin – Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Global Penicillin and Streptomycin – Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunities Analysis
5.3. Product/Market Life Cycle Analysis
6. Global Penicillin and Streptomycin– By Product Type
6.1. Penicillin
6.1.1. Bulk
6.1.2. Dosage
6.2. Streptomycin
6.2.1. Bulk
6.2.2. Dosage
7. Global Penicillin and Streptomycin Market – By Route of Administration
7.1. Oral
7.2. Intramuscular
7.3. Intravenous
8. Global Penicillin and Streptomycin Market – By Manufacturing process
8.1. Natural
8.2. Synthetic
8.3. Semi-synthetic
9. Global Penicillin and Streptomycin Market – By End User
9.1. Pharmaceuticals
9.2. Hospitals
9.3. Clinics/ ASC’s
10. Global Penicillin and Streptomycin Market – Geographic Analysis
10.1. Introduction
10.2. Americas
10.2.1. Canada
10.2.2. USA
10.2.3. Brazil
10.2.4. Others
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Spain
10.3.5. Netherlands
10.3.6. Others
10.4. APAC
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. South Korea
10.4.5. Australia
10.4.6. Others
10.5. ROW
11. Market Entropy
11.1. New Product Launches
11.2. M&As, Collaborations, JVs and Partnerships
12. Company Profiles (Overview, Financials, SWOT Analysis – Top 5 Companies, Developments, Product Portfolio)
12.1. Abbot Laboratories
12.2. Bristol Myers Squibb Co.
12.3. Johnson & Johnson
12.4. Pfizer
12.5. Amgen
12.6. Biogen Idec
12.7. Celgine Corporation
12.8. Merck & Co., Inc.
12.9. Gilead Sciences Inc.
12.10. Eli Lilly and Co
12.11. Astra Zeneca
12.12. Sanofi Aventis SA
12.13. GlaxoSmithKline Plc
12.14. Roche Pharmaceuticals
12.15. Novartis AG
12.16. Bayer HealthCare AG
12.17. Toyama Chemical Co., Ltd
12.18. Astellas Pharma Inc.
12.19. MiddleBrook Pharmaceuticals
12.20. Takeda Pharmaceutical Company
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
“”*Financials would be provided on a best efforts basis for private companies””
13. Appendix
13.1. Abbreviations
13.2. Sources
13.3. Research Methodology
13.4. Bibliography
13.5. Compilation of Expert Insights
14. Disclaimer”